Stock Analysis, Dividends, Split History

KPTI / Karyopharm Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price18.00
Volume454,800.00
Market Cap ($M)1,133.75
Enterprise Value ($M)1,014.78
Book Value ($M)213.47
Book Value / Share3.52
Price / Book5.31
NCAV ($M)201.44
NCAV / Share3.33
Price / NCAV5.63
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 49,533,150
Common Shares Outstanding 49,652,828
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.00
Return on Assets (ROA)-0.72
Return on Equity (ROE)-0.80
Balance Sheet (mrq) ($M)
Assets256.59
Liabilities43.12
Quick Ration/a
Current Ratio6.69
Income Statement (mra) ($M)
Sales Revenue Net0.00
Revenue From Grants0.00
License And Services Revenue1,605,000.00
Operating Income-130.54
Net Income-128.98
Earnings Per Share Basic And Diluted-2.81
Cash Flow Statement (mra) ($M)
Cash From Operations-73.72
Cash from Investing17.11
Cash from Financing-73.72
Identifiers and Descriptors
CUSIP48576U106
Central Index Key (CIK)1503802
Related CUSIPS
48576U956 48576U906

Split History

Stock splits are used by Karyopharm Therapeutics Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved

9h seekingalpha
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticals’s (ALNY) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation. (5-0)

Karyopharm Therapeutics: Can The Rally Continue?

2018-09-17 seekingalpha
The stock of Karyopharm Therapeutics has advanced some 65% over the past year as its main drug candidate has advanced. (2-0)

Your Daily Pharma Scoop: Karyopharm Buoyed, MediNova Succeeds, Ardelyx's Publication

2018-08-31 seekingalpha
Karyopharm Therapeutics (KPTI) reported that they plan to present, at the Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, data from their Phase 2b STORM study evaluating selinexor in heavily pretreated patients with refractory multiple myeloma (NYSE:MM). The presentation is scheduled on September 12-15. (39-5)

Your Cancer Highlight: Just How Far Can Karyopharm Go?

2018-08-30 seekingalpha
At an upcoming meeting, we will get a better look at how its drug is performing in this setting.

CUSIP: 48576U106